“We’ll Fix It Later”: Costly Lessons for Emerging Biopharma Leaders

Emerging biopharma companies are under pressure to spend carefully. That is hardly controversial. When you are a 40-person company working toward an investigational new drug (IND) filing, infrastructure does not compete for budget with other infrastructure. It competes with the next study.

Talk To Us

Talk Now